Author: Ravi Shankar

Initial deployment targets select employees, with potential to expand across the company’s broader workforce

Bond’s enterprise customers include two of the three largest companies in the world and one of the three largest credit card companies

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced that an S&P 500 financial technology company has selected Bond to provide personal security services for its executives and at-risk employees.

The agreement marks another enterprise customer win for Bond, adding to its growing presence across multinational corporations, municipalities and other organizations. The initial deployment will cover a select group of executives and at-risk employees, with the potential to expand across the company’s broader workforce over time. Many of Bond’s enterprise customers start with an initial deployment covering executives, their family members and specific at-risk employees, but have returned for additional licenses after their initial deployment, offering the Bond service across the broader workforce including employees in other countries.

Innovation creates new opportunities to accomplish personal and corporate goals. Protecting employees outside of the corporate facilities has been an extremely expensive task, which companies can practically only achieve relative to a few executives. Bond changes that reality with its category defining AI-powered Preventative Personal Security platform. Employees face potential risks while traveling, commuting and going about their daily lives, driving demand for security that is not limited by location. When employees experience violent incidents, in their professional or private lives – it is both tragic and expensive for the employers, given that corporations cover medical costs, absenteeism due to injuries, potential churn and the cost of hiring and training replacements. Bond addresses this need through its AI-powered platform, combining on-demand technology with trained Personal Security Agents who respond by video within seconds from its 24/7 Command Centers to help identify potential threats, prevent incidents from escalating and coordinate emergency assistance when needed. A study by Ernst & Young (EY) found that organizations offering Bond to their employees can expect savings of approximately $181 per employee per year, mainly from reduced medical costs, higher productivity and lower absenteeism.

“Companies have historically invested heavily in protecting their facilities, but that protection often ends when employees leave the building,” said Doron Kempel, Founder and Chief Executive Officer of Our Bond. “Bond addresses this gap by providing preventative personal security wherever employees are. Being selected by an S&P 500 company to protect its executives is an important validation of our platform. We see this as a starting point, and our goal is to earn the opportunity to protect more of the company’s employees over time. This approach of ‘land and expand’ is common in the B2B space and aligns with a reality of introducing a new paradigm for which there is no precedent of usage and initial budget allocation.”

About Bond
Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond offers personal security to more people than any other company globally. Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.25 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:
Crescendo Communications, LLC
212-671-1020
OBAI@crescendo-ir.com

Recognition highlights Vlasic’s leadership of Vertex’s enterprise AI and data transformation and her commitment to developing the next generation of women in technology

KING OF PRUSSIA, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Sarah Vlasic, Vice President of Enterprise Data and AI Workforce Productivity, has been named a winner of the 2026 Info-Tech Women Leading IT Award by Info-Tech Research Group. This award recognizes exceptional women who are championing technology, fostering inclusive workplaces, and inspiring the next generation of IT leaders. 

Vlasic leads Vertex’s enterprise-wide data and AI transformation. She helped build the company’s AI operating model, which takes AI out of pilots and into daily work in product development, go-to-market, services, and customer engagement. She is also responsible for establishing the governance framework, so AI can be used responsibly at scale, and for modernizing Vertex’s data foundation to give leaders reliable, real-time insights.

“Sarah has been instrumental in turning our AI-first vision into how Vertex actually works every day,” said Aneel Jaeel, Chief Operations Officer at Vertex. “She pairs strategic clarity with a real commitment to her people, and this recognition reflects the impact she’s had across our business and the broader technology community.”

Outside of her day-to-day role, Vlasic mentors women in technology as an active member of Vertex’s WISE (Women in Search of Excellence) community. She currently serves on the University of Nevada, Las Vegas (UNLV) Lee Business School Corporate Advisory Board and has led Leadership Circles at the University of Colorado Boulder, helping develop the next generation of women leaders in business and technology through industry expertise, thought leadership, and professional development.

“I’m incredibly grateful and honored to receive this recognition from Info-Tech. While my name may be on the award, it truly reflects the hard work, passion, and dedication of the incredible teams that are turning AI from a concept into real business value at Vertex,” said Vlasic. “I’m fortunate to work alongside people who challenge what’s possible every day, embrace new ways of working, and continuously push us forward. I’m especially proud to help create opportunities for women in technology to grow, lead, and make a meaningful impact, and I’m proud to be part of an organization that supports and encourages that journey.”

The 2026 Info-Tech Award winners were selected from a competitive pool of hundreds of nominees. The full list of 2026 winners is available at infotech.com/events/infotech-awards.

About Info-Tech Research Group 
Info-Tech Research Group is the “get things done” partner for over 30,000 IT, HR, and marketing leaders worldwide. The fastest growing research and advisory firm, Info-Tech enables leaders to make well-informed decisions and transform their organizations through AI, strategic foresight, step-by-step methodologies, practical tools, industry-leading advisory, and training programs. For nearly 30 years, tens of thousands of private and public organizations have trusted Info-Tech to lead their most important initiatives through periods of change and deliver outcomes that truly matter. 

To learn more about Info-Tech’s HR research and advisory services, visit McLean & Company, and for data-driven software buying insights and vendor evaluations, visit the firm’s SoftwareReviews platform. Media professionals can register for unrestricted access to research across IT, HR, and software, and hundreds of industry analysts through the firm’s Media Insiders program. To gain access, contact pr@infotech.com. 

For information about Info-Tech Research Group or to access the latest research, visit infotech.com and connect via LinkedIn and X. 

About Vertex  
Vertex is the Decision-to-Defense™ global indirect tax and compliance company. Vertex helps enterprises bring control to indirect tax and compliance across the full transaction lifecycle — from tax determination and e-invoicing through reporting, filing, and audit defense — to make outcomes easier to prove and improve over time. Trusted by more than 60% of the Fortune 500, Vertex combines decades of tax expertise, deep global tax and compliance knowledge, and embedded integrations to help organizations operate globally with confidence. With headquarters in North America and offices in South America and Europe, Vertex’s purpose is to ensure businesses and communities thrive through trusted transactions.

For more information, visit www.vertexinc.com or follow us on X and LinkedIn; or subscribe on YouTube.

Copyright © 2026 Vertex, Inc. All rights reserved. The information contained herein is intended for information purposes only, may change at any time in the future, and is not legal or tax advice. Any product direction and potential roadmap information is not a guarantee, may not be incorporated into any contract, and is not a commitment to deliver any material, code, or functionality. This information should not be relied upon in making purchasing, legal, or tax decisions. The development, release, and timing of any features or functionality described for Vertex’s products remains at the sole discretion of Vertex, Inc. Any statements in this release that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to various risks and uncertainties described in Vertex’s filings with the US Securities and Exchange Commission (“SEC”) that could cause actual results to differ materially from expectations. Vertex cautions readers not to place undue reliance on these forward-looking statements which Vertex has no obligation to update and which speak only as of their dates.

Vertex Company Contact: Simone Sonnier | Public Relations Manager | mediainquiries@vertexinc.com  

PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ326. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon

Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated

Denver, CO, Oct. 20, 2026 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect targeted intestinal exposure to PALI-0008, the active metabolite of PALI-2108, with PDE4 target engagement, reduced intestinal inflammation and early clinical activity in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD).

The new analyses build on previously reported Phase 1b results: a 47.5% reduction in mean endoscopic disease activity after 14 days in five patients with FSCD, and clinical response in all five patients in a separate UC cohort assessed after seven days. Palisade is enrolling the Phase 2b ASCENTRA-UC study and initiating a Phase 2a open-label study in Crohn’s disease.

“The strength of these findings is the connection between drug exposure at the site of disease, biological activity in intestinal tissue and early improvement on endoscopy,” said Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio. “In patients with longstanding fibrostenotic Crohn’s disease, most of whom were receiving biologic therapy, we observed endoscopic improvement within two weeks alongside reduced intestinal inflammation. Together with our UC findings, these results strengthen our confidence in advancing PALI-2108 as a once-daily oral treatment targeting both the ileum and colon. The exploratory tissue-remodeling signals also provide us with a compelling rationale to investigate its potential beyond inflammation.”

Rapid Endoscopic Improvement in Fibrostenotic Crohn’s Disease

Oral presentation OP003, presented by Florian Rieder, M.D., Cleveland Clinic, describes a Phase 1b open-label study in five patients with symptomatic ileal strictures and a mean disease duration of 15.4 years. Four of five patients were receiving concomitant biologic therapy. Patients received PALI-2108 once daily with food over 14 days, with titration to target doses of 20, 25 or 30 mg.

• Previously reported endoscopic activity: Mean Simple Endoscopic Score for Crohn’s Disease (SES-CD) decreased by 47.5%. Two of five patients (40%) achieved endoscopic response, and two of five (40%) achieved endoscopic remission, defined as an SES-CD of 0–2.
• Reduced intestinal inflammation: Mean fecal calprotectin decreased by 58.8% from baseline. Ileal tissue cAMP increased, consistent with PDE4 target engagement; exploratory analyses identified an inverse association between changes in tissue cAMP and fecal calprotectin.
• Evidence of tissue-level activity: Paired biopsy analyses showed reductions in inflammatory-cell populations. Exploratory single-nucleus RNA analyses identified reduced PDE4D expression in ileal enterocytes in three of four patients with paired sprovamples.
• Exploratory stricture observation: One stricture that could not be traversed by the endoscope at baseline was traversable at Day 14. This single-patient observation does not establish reversal of fibrosis.
• Favorable short-term tolerability: All reported adverse events were mild. No serious adverse events, treatment discontinuations, nausea, vomiting, diarrhea or headache were reported in this five-patient cohort.

Exploratory changes in collagen-degradation and macrophage-associated biomarkers were consistent with potential extracellular matrix remodeling and support further investigation of PALI-2108’s effects on fibrotic disease. These analyses do not establish an antifibrotic clinical benefit.

Early Clinical Activity and Histologic Improvement in Ulcerative Colitis

Moderated poster MP0844 builds on previously reported findings from five patients in the Phase 1b UC cohort, which evaluated titration to 30 mg twice daily. At the Day 7 assessment, all five patients achieved clinical response and two achieved clinical remission. Tissue analyses showed reductions in inflammatory-cell populations and improvements in histologic disease activity, alongside evidence of PDE4 target engagement.

These findings support ASCENTRA-UC, the ongoing Phase 2b study evaluating PALI-2108 at 15 mg and 30 mg once daily versus placebo in approximately 204 patients.

Intestinal Drug Exposure Supports Once-Daily Development

Moderated poster MP0564 further characterizes PALI-2108’s targeted delivery profile. In evaluated FSCD patients, mean intestinal tissue concentrations of active PALI-0008 were approximately 7.3-fold higher than peak plasma concentrations, with exposure demonstrated in the ileum, ascending colon and descending colon. Pharmacokinetic findings also supported sustained plasma exposure above the estimated PDE4 IC90, the concentration associated with 90% inhibition in vitro, over 24 hours at 30 mg once daily.

Together, these findings support the development of a once-daily oral therapy designed to concentrate PDE4 activity in intestinal tissue while providing sustained systemic exposure with a more gradual rise in plasma drug concentrations.

Transcriptomic Analyses Support Biomarker Development

Moderated poster MP0845 describes an exploratory analysis of approximately 3,000 transcriptomic samples from more than 15 studies. Composite signatures incorporating PDE4/cAMP signaling and inflammatory pathways improved separation of responder and non-responder phenotypes compared with PDE4 gene expression alone. The work supports further investigation of biomarkers that may help characterize treatment response; prospective predictive utility for PALI-2108 has not been established.

The UC and FSCD clinical findings are exploratory and derive from small, short-duration, open-label cohorts without placebo controls. They require confirmation in larger controlled studies. The studies do not establish comparative efficacy or safety, durable benefit, or reversal of intestinal fibrosis.

The presentations are available on the Publications page of the Company’s website.

About PALI-2108

PALI-2108 is an investigational oral PDE4 inhibitor prodrug designed for localized bioactivation in the terminal ileum and colon and being developed for once-daily dosing. Its active metabolite, PALI-0008, inhibits PDE4, increasing intracellular cAMP to modulate inflammatory signaling. Phase 1 studies have provided evidence of intestinal exposure, target engagement, favorable short-term tolerability and early clinical activity, supporting Phase 2 development in UC and Crohn’s disease. PALI-2108 has not been approved for any indication.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. Its lead program, PALI-2108, is advancing through Phase 2 development in inflammatory bowel disease.

For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing, durability of effect or pharmacological properties, observed from preclinical or clinical trials (such as our Phase 1b findings) with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

Nov. 3 at 4:30 p.m. EST

IRVINE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions will host a conference call with analysts to discuss its fourth quarter fiscal 2026 results and business outlook on Nov. 3, 2026, at 4:30 p.m. EST.

After the close of the market on Nov. 3, and prior to the conference call, Skyworks will issue a copy of the earnings press release via GlobeNewswire. The press release may also be viewed on Skyworks’ website at www.skyworksinc.com/investors.

To listen to the conference call, please visit the investor relations section of Skyworks’ website at https://investors.skyworksinc.com/events-presentations. Playback of the conference call will be available on Skyworks’ website at www.skyworksinc.com/investors beginning at 9 p.m. EST on Nov. 3. Additionally, a transcript of the company’s prepared remarks will be made available on our website promptly after their conclusion during the call.

About Skyworks
Skyworks® is a global leader in high-performance RF, precision timing, power management and mixed-signal solutions that power the intelligent, connected world. Through deep engineering expertise, Skyworks helps customers address rising complexity and deliver seamless connectivity across smartphones, vehicles, networks and critical infrastructure.

From defense and aerospace systems to the connected edge, AI infrastructure and next-generation automotive platforms, Skyworks provides the essential technologies that connect, synchronize and power physical AI, as intelligence moves out of the data center and into the real world. Harnessing decades of technical leadership and trusted partnerships across the technology ecosystem, Skyworks helps the world’s leading innovators bring next-generation products and services to market.

Skyworks is a member of the S&P 500® market index (Nasdaq: SWKS). For more information, please visit www.skyworks.com.

Safe Harbor Statement
Any forward-looking statements contained in this press release are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include without limitation information relating to future events, results and expectations of Skyworks. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “forecasts,” “intends,” “believes,” “plans,” “may,” “will” or “continue,” and similar expressions and variations or negatives of these words. Actual events and/or results may differ materially and adversely from such forward-looking statements as a result of certain risks and uncertainties, including those identified in the “Risk Factors” section of Skyworks’ most recent Annual Report on Form 10-K (and/or Quarterly Report on Form 10-Q) as filed with the Securities and Exchange Commission (“SEC”). Copies of Skyworks’ SEC filings can be obtained, free of charge, on Skyworks’ website (www.skyworksinc.com) or at the SEC’s website (www.sec.gov). Any forward-looking statements contained in this press release are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Note to Editors: Skyworks and the Skyworks symbol are trademarks or registered trademarks of Skyworks Solutions, Inc., or its subsidiaries in the United States and other countries. Third-party brands and names are for identification purposes only and are the property of their respective owners.

Media Relations:         Constance Griffiths (949) 230-4867         Constance.Griffiths@skyworksinc.com

Investor Relations: Raji Gill (949) 508-0973 Raji.Gill@skyworksinc.com

New collaboration will bring Capitalization Table data to FactSet Workstation, strengthening and expanding its private markets offering for investment professionals

NORWALK, Conn., Oct. 20, 2026 (GLOBE NEWSWIRE) — FactSet, a leading global intelligence and AI solutions provider to the financial markets, has entered into a partnership with Nasdaq Private Market (NPM), a leading provider of liquidity, capital and investment solutions for private companies and investors, to integrate Capitalization (Cap) Table data into its platform. The intelligence sourced from NPM is expected to support more informed due diligence, valuation analysis, and deal sourcing – areas where reliable, structured data has historically been difficult to obtain.

The partnership comes at a particularly relevant moment. While private markets have grown significantly over the past decade, transparency, reporting standards, and data-sharing practices have struggled to keep pace. As investment professionals across all firm types are allocating more capital to private assets, the need for accurate, structured private markets data has grown sharply.

FactSet’s collaboration with NPM directly addresses this need. The integrated solution will give investment professionals a deeper insight into private company ownership structures and how financing transactions, such as new funding rounds, secondary sales, and dilutive events, affect ownership stakes and capital structure over time.

Critically, the Cap Table data sourced through NPM is supported by verifiable, auditable documentation and filings, rather than relying solely on modelled ownership estimates. This will provide financial and advisory firms with a higher degree of confidence in the data underpinning their investment and dealmaking workflows.

The NPM data also complements the private-company, funding, deal, and M&A data FactSet already provides. This enables clients to develop a more complete and connected view of private-market activity, spanning a company’s early funding history through to its current ownership and capital structure.

“Private markets have grown significantly, but the underlying ownership data hasn’t kept pace. As a result, firms have largely relied on modelled estimates rather than source documents. As an active secondary trading venue and private company share settlement engine, Nasdaq Private Market operates differently, working directly with the legal documentation that underpins private company ownership. The unique access to high-quality source data forms the basis of our partnership. The agreement also reflects FactSet’s ongoing commitment to expanding our private markets capabilities and ensuring clients have access to comprehensive, high-quality data across both public and private markets, all within a single platform.” – said Eric Weitzman, Senior Vice President, Senior Director of Data Partnerships at FactSet.

“Cap table data and in particular, share-class level information, is fundamental to how investment professionals evaluate private company investment opportunities and potential outcomes, and we are pleased to be working with FactSet to make this data more accessible to the market,” – said James Brooks, Chief Strategy Officer at Nasdaq Private Market.

The partnership reflects FactSet’s continued investment in private markets data capabilities and commitment to provide a top-grade trusted financial intelligence for all firm types across public and private markets within a unified ecosystem.

About FactSet

FactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that help our clients maximize their potential. Our cutting-edge digital platform seamlessly integrates proprietary financial data, client datasets, third-party sources, and flexible technology to deliver tailored solutions across the buyside, sell side, wealth management, private equity, and corporate sectors. With over 48 years of expertise, a presence in 20 countries, and extensive multi-asset class coverage, we leverage advanced data connectivity alongside AI and next-generation tools to streamline workflows, drive productivity, and enable smarter, faster decision-making. Serving more than 9,200 global clients and over 260,000 individual users, FactSet is a member of the S&P 500 dedicated to innovation and long-term client success.
Learn more at www.factset.com and follow us on X and LinkedIn.

About Nasdaq Private Market

Nasdaq Private Market is a leading provider of liquidity, capital, and investment solutions for private companies, employees, and investors. The company is focused on building modern infrastructure for the private market ecosystem, including technology for company-sponsored liquidity events, a settlement engine for private shares, a marketplace for buying and selling private company stock and funds, and data and intelligence on the private market. Nasdaq Private Market also helps connect private companies to capital through primary fundraising and capital introduction. For more information, visit nasdaqprivatemarket.com.

FactSet Investor Relations:
Kevin Toomey
+1.212.209.5259
Kevin.toomey@factset.com

FactSet Media Relations:
Alexandra Shevchenko
Oleksandra.shevchenko@factset.com

NPM Media Relations:
Samantha Tortora
press@npm.com

Calibration Guidelines bring recommendations from leading providers into repair and claims workflows to support proper and consistent vehicle repairs

CHICAGO, Oct. 20, 2026 (GLOBE NEWSWIRE) — As advanced driver assistance systems (ADAS) become more common and complex, repairers and insurers need trusted calibration guidance at the point of decision. CCC Intelligent Solutions Inc. (CCC), a leading SaaS and AI platform powering the insurance and repair economy, today announced Calibration Guidelines, a new capability that brings recommendations from leading providers directly into existing estimating workflows.

“The growing complexity of today’s vehicles is raising the stakes for every participant in the repair ecosystem,” said Dan Risley, vice president, Automotive Services Group for CCC. “Supporting safe, proper, and consistent repairs requires collaboration across repairers, insurers, automakers, diagnostics providers, and technology partners. CCC is helping make trusted calibration guidance easier to access and apply as repair and claims decisions are being made.”

Industry stakeholders, including leading repair associations and consumer advocacy groups, have increasingly identified ADAS calibrations as one of the collision repair industry’s most pressing issues, citing the need for easier access to trusted repair guidance.

“ADAS represents one of the most significant technological changes our industry has ever faced,” said Erick Bickett, Director, PACE Calibration Centers. “The pace and magnitude of this change demand collaboration across the entire industry. We appreciate CCC’s leadership in making calibration guidance more accessible at the point where critical repair decisions are made and for their work as part of CIECA’s ADAS Calibration Committee. Together, these efforts are important steps toward greater transparency and proper repairers.”

CCC’s Calibration Guidelines sources recommendations, informed by vehicle manufacturers’ repair and calibration requirements, from leading calibration and diagnostics providers. Current participants include asTech (via adasThink), Azimuth, Opus (via ADAS Map Pro), Kinetic and REVV.

“No single stakeholder can solve this challenge alone,” Risley added. “The industry’s continued focus on ADAS calibration reflects a shared commitment to consumers, safer roadways, and the proper repair of increasingly sophisticated vehicles. CCC is proud to support those efforts by helping connect trusted information with the people who need it.”

Calibration Guidelines is available to all CCC ONE users at no additional cost from CCC. Customers with a contracted participating provider can access recommendations through the Diagnostics button in CCC ONE; insurers using Advanced or Intelligent Estimating in APEX can also access the capability.

Visit cccis.com/diagnostics to learn more.

About CCC
CCC Intelligent Solutions Holdings Inc. (NASDAQ: CCC) is a leading SaaS and AI platform powering the multi-trillion-dollar insurance and repair economy. CCC connects more than 35,000 businesses, including insurers, repairers, automakers and parts suppliers, through the workflows where claims and repair decisions are made every day. With AI built into those workflows for over a decade and informed by more than 40 years of industry data, CCC helps customers manage growing complexity and move work forward with confidence. Through purposeful innovation and the strength of its network, CCC helps keep people’s lives moving forward when it matters most. Learn more about CCC at www.cccis.com.

Special Note Regarding Forward-Looking Statements 

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding future use and performance of CCC’s digital solutions. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, competition, including technological advances and new products marketed by competitors; changes to applicable laws and regulations; and other risks and uncertainties, including those included under the header “Risk Factors” in CCC’s filings with the Securities and Exchange Commission (“SEC”), including the Form 10-K filed February 24, 2026, which can be obtained, without charge, at the SEC’s website (www.sec.gov). The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 

CCC Media Contact: Michelle Hellyar
mhellyar@cccis.com | 773.791.3675

WEST PALM BEACH, Fla., Oct. 20, 2026 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“AFC”) today announced that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, before market open. Management will review AFC’s financial results at 10:00 am ET via webcast available on the Investor Relations section of AFC’s website found here AFC — Investor Relations. Participants are also invited to access the conference call by registering in advance at this link. A replay will be available one hour after the event.

AFC distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.

About AFC

AFC (Nasdaq: AFCG) is a publicly traded business development company that provides flexible credit solutions to lower middle-market companies. The company primarily originates, structures, invests and manages direct senior debt investments, targeting companies generating annual EBITDA of $5 to $50 million. The company seeks to maximize risk-adjusted returns for its stockholders with an opportunistic approach across all industries. AFC is headquartered in West Palm Beach, Florida. For additional information regarding the company, please visit www.afcbdc.com.

Investor Relations Contacts

Robyn Tannenbaum // Will Rotatori
561-510-2293 // 561-510-6109
ir@afcbdc.com

Media Contact

Jim Velgot
561-510-1416
ir@afcbdc.com

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.

Key Collaboration Highlights

• Clinically Validated Data: The Assessment was developed in collaboration with three Taipei Medical University (TMU) affiliated hospitals and validated using over 1,200 clinical records.
• Broad Immediate Reach: JoiiUp brings over 12 years of workplace health promotion experience, actively supporting the employee wellness programs of over 400 companies.
• Non-Invasive Profiling: The tool utilizes an online health questionnaire and proprietary AI models mapped against medical literature to analyze demographic data, lifestyle habits, and family history across ten cancer types—requiring no blood draws or imaging.
• Actionable Digital Integration: By leveraging Single Sign-On (SSO), users can seamlessly access the Assessment directly within the JoiiSports app to generate personalized risk reports and targeted lifestyle recommendations.

Strategic Market Integration

The integration will connect the Assessment with JoiiUp’s existing exercise, nutrition, and sleep management ecosystem. Initial deployment is expected to focus on JoiiUp’s existing corporate partner network, enabling employers to seamlessly add targeted cancer risk analysis to their employee health benefits. Following successful corporate implementation, the companies plan to expand the offering to healthcare institutions as a supplementary tool for patient education and consultation.

Management Perspectives

“A key to cancer prevention is understanding risk early and taking timely action,” said Dr. Ethan Shen, Chairman and CEO of YD Bio. “This Assessment is the first step in building a comprehensive cancer management pathway spanning risk assessment, early detection, and precision medicine. Through JoiiUp, we are bringing personalized risk analysis directly into everyday health management and supporting vital follow-up discussions with healthcare professionals.”

Dr. Ruo-Kai Lin, Professor at TMU and Chief of R&D at EG BioMed, noted: “Through questionnaires and personalized analysis, we hope to help users understand their risks and inform discussions with healthcare professionals. Partnering with JoiiUp makes this clinically validated information vastly more accessible.”

Important Regulatory Disclosure

The Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction, or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing, or consultation with a qualified healthcare provider, and does not replace recommended cancer screening.

About JoiiUp

JoiiUp delivers smart health management and digital health services. Its JoiiSports app combines wearable devices, exercise and nutrition management, and AI health applications to build healthy lifestyles. The JoiiCare platform provides wellness activities and health management tools for over 400 corporate clients. For more information, visit www.joiiup.com.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy and operations; and the planned partnership with EG BioMed and JoiUpp, along with the associated integration of the Assessment into the JoiiSports app, the implementation approach, the anticipated commercial and strategic benefits of the partnership and related future expansion plans. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “hope,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including system integration and implementation challenges; corporate client requirements; consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:

YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships

PRINCETON, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the appointments of John Dawson CBE, Deborah Ramsdell, and Bruce Wendel to the Company’s Board of Directors (the “Board”), effective as of October 18, 2026. The appointments follow the resignations of Stephen Glover, Kamil Ali-Jackson, Esq., Gregory Freitag, J.D., CPA, and Otis Brawley, M.D., effective October 18, 2026.

“On behalf of the Board, I am delighted to welcome three such accomplished pharma industry executives to PDS Biotech,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “John, Deborah and Bruce have had extraordinarily distinguished careers, and bring deep experience in drug development, commercialization, regulatory affairs and partnership negotiations to our Board. We expect their perspectives to support the Company as we advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue our partnership strategy for PDS0101.”

Dr. Bedu-Addo added, “I also extend the Board’s thanks to Stephen, Kamil, Greg and Otis for their contributions to PDS Biotech in shaping the Company’s clinical development strategy. In particular, Otis’ distinguished oncology experience played an important role in shaping the Company’s clinical development strategy. We are grateful for their guidance and many contributions.”

The reconstituted Audit Committee comprises Mr. James Banaag (Chair), Mr. John Dawson and Mr. Bruce Wendel. The Compensation Committee comprises Dr. Patrick Soon-Shiong (Chair), Mr. James Banaag and Mr. John Dawson. The Nominating and Governance committee consists of Mr. Bruce Wendel (Chair), Ms. Deborah Ramsdell and Dr. Ilian Iliev.

About the New Directors

Mr. John A. Dawson CBE has served as Executive Chair of Virocell Therapeutics, a privately held cell and gene therapy company, since March 2023. Since January 2023, he has served as a non-executive director and chair of the audit and risk committee of Norgine, a privately held specialty pharmaceutical company, and since June 2022, he has served as a non-executive director of Chinese Specialty Pharma Ltd., a privately held specialty pharmaceutical company. From February 2022 to January 2024, Mr. Dawson served as a non-executive director, senior independent director and chair of the audit and remuneration committees of Ergomed plc. From August 2008 to January 2022, he served as Chief Executive Officer of Oxford Biomedica plc and remained a member of its board of directors until May 2022. During his tenure as CEO, he rejuvenated the company’s drug development and LentiVector platform, and elevated the company to a leading position in the world of cell and gene therapy. He secured deals with companies with Sanofi, Novartis, Orchard Therapeutics, Boehringer Ingelheim and Axovant with total value in excess of $1.75bn. From 1997 to 2007 Mr. Dawson was head of Europe for Cephalon. During his tenure at Cephalon he played multiple roles within the organization including CEO Pharmaceutical Operations Europe, Country Manager UK & Senior European Financial Director and European Financial Director. At Cephalon Mr. Dawson led several deals during which the market capitalization of the company grew from $150m to $1b. Mr. Dawson holds a B.Sc. (Hons) in Mathematics from the University of Swansea and is a member of the Institute of Chartered Accountants in England and Wales.

Ms. Deborah A. Ramsdell, a regulatory expert, brings more than 35 years of experience in leadership roles at early- and clinical-stage biotechnology companies, with broad regulatory expertise in drug development, including rare disease drug development. Over the course of her career, she has been responsible for the strategic design, leadership and operational oversight of multiple drug candidates in the fields of oncology, rare metabolic diseases, dermatology, pain, infectious diseases, transplantation, cardiology, renal diseases, and endocrinology. Between 2010 and 2018 she served as Executive Team/Board of Director member for four biotechnology companies that were sold to pharmaceutical/biotech companies for $350M – $1.1B. Since August 2026, Ms. Ramsdell has served as Chief Executive Officer of Pluvia Biotech, a privately held clinical-stage company developing a therapy for phenylketonuria. Since 1996, she has been the owner of CMS International, Inc., a healthcare consulting firm. From February 2021 to July 2024, she served as co-founder and Chief Executive Officer of Phoenicis Therapeutics, a privately held clinical-stage biotechnology company, and from January 2013 to May 2020, she served as President and Chief Executive Officer of Valerion Therapeutics, a privately held biotechnology company. Ms. Ramsdell holds a B.S. in Biology and M.Ed. in Special Education from Boston College.

Mr. Bruce Wendel has had several leading roles at top tier pharmaceutical and biotech companies. As EVP of Corporate Development at Bristol-Myers Squibb Company he led negotiations of M&A transactions, licensing and co-promotion deals and divestitures globally. From April 2018 to May 2019, he served as Chief Business Development Officer for ProMetic Biosciences Ltd., a pharmaceutical development company, and he also served as a director of ProMetic Biosciences Ltd. He also served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company, from July 2012 to July 2018 and as Chief Executive Officer of Scientific Protein Laboratories, LLC from December 2014 to June 2015. Prior to this, having served in roles of increasing responsibility at Abraxis BioScience, LLC, he was appointed Vice Chairman and Chief Executive Officer, overseeing the commercialization of Abraxane® and leading the negotiations that culminated in the acquisition of the company by Celgene Corporation in 2010. He was also Vice President of Business Development at IVAX Corporation, and at American Pharmaceutical Partners, Inc. From November 2020 to May 2025, he served on the board of directors of GT BioPharma, Inc., and from June 2016 through May 2021, he served on the board of directors of Verastem, Inc. He currently serves on the board of ImmunityBio. He earned a juris doctor degree from Georgetown University Law School, and a B.S. from Cornell University.

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune® HPV), PDS0103 (Versamune® MUC1) and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Jude Gorman / Kiki Torpey
Collected Strategies
PDS-CS@collectedstrategies.com